Toggle light / dark theme

Hypotension is a common complication during general anesthesia associated with increased postoperative mortality and morbidity. Every episode of intraoperative hypotension, regardless of duration, is linked to the risk of acute kidney injury and cardiovascular events. The vulnerability to hemodynamic disturbances increases with age, underscoring the need for prompt interventions for elderly patients who experience hypotension during anaesthesia.

Using ephedrine resulted in a notable rise in mean arterial pressure (MAP) and cardiac output (CO). Still, no meaningful correlation with age was detected in patients aged 45 years or older. These results imply that ephedrine is reliable for managing low blood pressure during general anaesthesia, even in elderly patients, says Yuta Uemura in a recent study published in BMC Anesthesiology.

Ephedrine is a mixed α- and β-agonist vasopressor for correcting hypotension during general anaesthesia. β-responsiveness decreases with age; therefore, this study aimed to determine whether ageing would reduce the pressor effect of ephedrine on hypotension during general anaesthesia.

Scientists have found a way to reprogram human cells so that they mimic the highly plastic embryonic stem cells that have so much promise for use in regenerative medicine. By essentially wiping the cell’s “memory”, the team have created so-called induced pluripotent stem (iPS) cells, which could be used to regenerate or repair diseased tissue and organs.

IPS cells are a type of pluripotent cell that can be obtained by reprogramming mature human adult cells (“somatic” cells) into an embryonic stem cell-like state. This means that they have the capacity to differentiate into any cell of the body. They were first demonstrated in 2006, and have myriad potential biomedical and therapeutic uses, including disease modeling, drug screening, and cell-based therapies.

Despite this promise, researchers have continually hit a stumbling block that has prevented iPS cells from realizing their potential. “A persistent problem with the conventional reprograming process is that iPS cells can retain an epigenetic memory of their original somatic state, as well as other epigenetic abnormalities,” Professor Ryan Lister, lead author of a paper presenting the latest breakthrough, said in a statement.

In this video, we’ll dive deep into the cutting-edge research on how Artificial Intelligence (AI) and Artificial General Intelligence (AGI) are helping us to better understand the aging process and unlock the secrets to living forever.

We’ll discuss the latest breakthroughs in AI and AGI and how they are enabling researchers to analyze vast amounts of data, identify patterns, and make predictions that were once impossible. We’ll also explore how AI and AGI are being used to develop new treatments and therapies to prevent or reverse aging-related diseases within the Longevity Industry.

The successful transfer of a gene that produces HMW-HA paves the way for improving the health and lifespan of humans, too. In a groundbreaking endeavor, scientists at the University of Rochester have successfully transferred a longevity gene from naked mole rats to mice, leading to enhanced health and increased lifespan. Naked mole rats, noted for their resistance to age-related diseases, have a gene that produces high molecular weight hyaluronic acid (HMW-HA), which when introduced to mice, demonstrated potential anti-aging benefits.

So past the 7 minute mark we see a competing interest may have stumbled upon the same thing so Katcher and gang are starting a company to commercialize E5.


Here we review a preprint from Dr Katcher and Dr Horvath giving more detail on the experiments which showed a 54% epigenetic rejuvenation in rats and reveals the source of E5 and the processing involved.

Renue By Science 10% : https://tinyurl.com/35jyuk33

Get my new Longevity Practices book for free: https://www.diamandis.com/longevity.

In this episode, filmed during Abundance360, Peter and David discuss David’s groundbreaking research on reversing aging through epigenetic changes, emphasizing that aging is not just damage to the body but a loss of information. They talk about age reversal as a possibility, rejuvenating brains, and regaining lost memories.

David Sinclair is a biologist and academic known for his expertise in aging and epigenetics. Sinclair is a genetics professor and the Co-Director of Harvard Medical School’s Paul F. Glenn Center for Biology of Aging Research. He’s been included in Time100 as one of the 100 Most Influential People in the World, and his research has been featured all over the media. Besides writing a New York Times Best Seller, David has co-founded several biotech companies, a science publication called Aging, and is an inventor of 35 patents.

Read Sinclair’s latest study, Chemically Induced Reprogramming to Reverse Cellular Aging: https://www.aging-us.com/article/204896/text.